Ceribell (CBLL) Rose 91% after Reporting Inline Financial Results

1 hour ago 2

Soumya Eswaran

Thu, April 2, 2026 astatine 8:43 AM CDT 3 min read

TimesSquare Capital Management, an equity concern absorption company, released its “U.S. Small Cap Growth Strategy” fourth-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The strategy returned 3.70% (gross) and 3.45% (net) successful the 4th fourth compared to a 1.22% instrumentality for the Russell 2000 Growth Index. In 2025, the strategy returned 6.91% (gross) and 5.85% (net) compared to 13.01% for the index. Global equity markets ended the 4th connected a affirmative note, with Europe leading, followed by Emerging Markets. In astir markets, ample caps outperformed tiny caps. The commercialized truce betwixt the United States and China was prolonged for an further year, but planetary geopolitical concerns, whether related to tariffs oregon not, persisted. Third-quarter GDP exceeded expectations, but user caution persists amid ongoing labor-market softening, influencing the Fed’s determination connected interest-rate cuts. Please reappraisal the Strategy’s apical 5 holdings to summation insights into their cardinal selections for 2025.

In its fourth-quarter 2025 capitalist letter, TimesSquare Capital U.S. Small Cap Growth Strategy highlighted CeriBell, Inc. (NASDAQ:CBLL). CeriBell, Inc. (NASDAQ:CBLL) is aesculapian exertion institution specializing successful processing a caller and point-of-care EEG platform. On April 1, 2026, CeriBell, Inc. (NASDAQ:CBLL) closed astatine $18.50 per share. One-month instrumentality of CeriBell, Inc. (NASDAQ:CBLL) was 3.41%, and its shares mislaid 1.23% implicit the past 52 weeks. CeriBell, Inc. (NASDAQ:CBLL) has a marketplace capitalization of $696.36 million.

TimesSquare Capital U.S. Small Cap Growth Strategy stated the pursuing regarding CeriBell, Inc. (NASDAQ:CBLL) successful its 4th fourth 2025 capitalist letter:

"Our preferences among Health Care stocks are those companies providing caller therapies for unmet needs that bid premium pricing, oregon specialized work providers. The stock terms of CeriBell, Inc. (NASDAQ:CBLL), a person successful portable electroencephalogram (EEG) technology, surged 91% aft reporting inline fiscal results and elevating its income outlook for the remainder of its fiscal year. The caller FDA clearance for the company’s Clarity algorithm for neonates importantly broadens Ceribell’s full addressable markets and is expected to alteration an earlier-than-anticipated neonatal launch."

7 Best Medical Device Stocks To Buy Right Now

CeriBell, Inc. (NASDAQ:CBLL) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 20 hedge money portfolios held CeriBell, Inc. (NASDAQ:CBLL) astatine the extremity of the 4th quarter, up from 12 successful the erstwhile quarter. While we admit the imaginable of CeriBell, Inc. (NASDAQ:CBLL) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article